SEC Filing Summary: Ventrus Biosciences, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ventrus Biosciences, Inc. on September 11, 2013. The report discloses a material event regarding the company's clinical development program. Note: The input metadata references "Assembly Biosciences, Inc.," but the filing text explicitly identifies the registrant as "Ventrus Biosciences, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate event rather than periodic financial performance.
Material Changes and Events
- Clinical Study Results: On September 11, 2013, the company announced positive results from clinical dermal safety and pharmacokinetic studies of its candidate drug, diltiazem (Ven 307).
- Disclosure Method: The announcement was made via a press release, which is attached as Exhibit 99.1 and incorporated by reference.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the announcement of the positive study results. The report does not mention unusual items or management commentary outside the referenced press release.
Investor Verification Checklist
- Verify the full details of the positive dermal safety and pharmacokinetic results for Ven 307 in the attached press release (Exhibit 99.1).
- Confirm the current corporate name and status, as the metadata lists "Assembly Biosciences" while the filing lists "Ventrus Biosciences."
- Review subsequent filings for any financial impact or strategic changes resulting from these clinical results.